Results

1–10 of 12 results for Robert L. Avery

1-Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD
Robert L. Avery, MD
Updates from the Field
2025
Modulation of Macrophages and Complement Dysfunction in Nonexudative AMD Utilizing Novel Sialic Acid-Coated Nanoparticles
Robert L. Avery, MD
Updates from the Field
2024
Comparison of Hypochlorous Acid vs. Povidone Iodine Use Prior to Intravitreal Injection: A Randomized Prospective Trial Study
Robert L. Avery, MD
Annual Meeting Talks
2021
Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD
Robert L. Avery, MD
Updates from the Field
2021
Therapeutic Horizons for Dry AMD
Robert L. Avery, MD
Updates from the Field
2019
AMD Neovascular Expert Panel
Robert L. Avery, MD
Nizar S Abdelfattah, M.D.
Nancy M. Holekamp, MD, FASRS
Peter K. Kaiser, MD FASRS
Pravin U. Dugel, MD
Annual Meeting Talks
2016
Potential Safety Concerns of Bevacizumab for Retinopathy of Prematurity
Robert L. Avery, MD
Annual Meeting Talks
2016
My Practice is Worth WHAT? Equity Acquisition in the Retina World
Robert L. Avery, MD
Carl W. Baker, MD, FASRS
Michael S. Jacobson, MD
Reginald J. Sanders, MD, FASRS
Annual Meeting Talks
2018
Do Anti-VEGF Injections Affect the Development of Neovascular AMD in Fellow Eyes? A Meta-analysis of Clinical Trials
Robert L. Avery, MD
Annual Meeting Talks
2018
Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients Treated With Intravitreal Aflibercept or Ranibizumab in the VIEW studies
Robert L. Avery, MD
On Demand Cases, Courses, and Papers
2017